Making the connections that develop into advanced therapeutics and long, happy relationships.

About Aratana



From both a scientific and emotional perspective, it’s an exciting time to be part of the animal health industry. Many therapeutics in development for humans have great potential to help solve unmet medical needs in pets. At the same time, dogs and cats are living longer as cherished members of the family who merit the quality of care these potentially new therapeutics can offer.

Aratana Therapeutics is positioned at the intersection of the best of human science and veterinary medicine. Both humans and pets are experiencing some of the same health concerns, such as how to manage pain and inappetence, as well as effective and tolerable treatments for cancer, viral diseases and allergy. Veterinarians currently have relatively few prescription medicines at their disposal that have been specifically approved for use in pets to meet these growing needs.

An ideal product for potential in licensing will have demonstrated some very specific criteria:

  • Proof of safety in the target species
  • Proof of efficacy in at least two mammalian species
  • Well-defined manufacturing process for the active pharmaceutical ingredient (for small molecule drugs)

We are seeking and reviewing therapeutic opportunities in many areas of pet health, including:
Cardiovascular Disease
Dental Diseases
GI Diseases
Infectious Diseases
Kidney Diseases
Lung Diseases
Post-operative Pain
Urinary Tract Disorders


If you or your company would like to explore innovative business opportunities with Aratana Therapeutics, please contact us:
Jeff Jones
Vice President Business Development


If you are interested in investing in Aratana Therapeutics, Inc., you can find us at NASDAQ: PETX. View all other investor information here.

You may also explore career opportunities with Aratana here.

Related News Posts

Aratana, Elanco Announce Global Strategic Collaboration

Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced a licensing agreement for Aratana’s FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs.